Improving survival and reducing treatment side effects in childhood leukaemia

Cancer is the most common cause of childhood disease-related deaths, and acute lymphoblastic leukaemia (A.L.L) is the most common childhood cancer. Whilst remission is achievable in 95% of cases, approximately 1/3 of patients will relapse (re-develop cancer), and 20-30% of children with leukaemia will not be long-term survivors. The major cause of relapse is drug resistance.  We have developed a new drug that can kill A.L.L cells whilst leaving normal peripheral blood mononuclear and bone marrow cells untouched. The ultimate goal of this project is to develop a new therapy for childhood leukaemia that improves survival, without increasing side effects and toxicity associated with treatment.

Research Area 
Project type 
Project Grant
Year of funding 
2013